Compounds > 3,3'-methyliminobis(n-methylpropylamine)
Page last updated: 2024-11-06

3,3'-methyliminobis(n-methylpropylamine)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,3'-methyliminobis(N-methylpropylamine): neurotoxic triamine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67161
SCHEMBL ID1231390
MeSH IDM0103912

Synonyms (43)

Synonym
LS-13732
1,3-propanediamine, n,n'-dimethyl-n-[3-(methylamino)propyl]-
n,n',n-trimethyldiitrimethylenetriamine
nsc-166322
1, n,n'-dimethyl-n-[3-(methylamino)propyl]-
3,3'-methyliminobis(n-methylpropylamine)
nsc166322
123-70-6
n,n'-dimethylmethyliminobis(dipropylamine)
3,3'-bis(methylamino)-n-methyldipropylamine
dipropylamine,3'-bis(methylamino)-
n,n-bis[3-(methylamino)propyl]methylamine
n,n'-dimethyl-n'-[3-(methylamino)propyl]propane-1,3-diamine
1,3-propanediamine, n1,n3-dimethyl-n1-(3-(methylamino)propyl)-
dipropylamine, n-methyl-3,3'-bis(methylamino)-
1,3-propanediamine, n,n'-dimethyl-n-(3-(methylamino)propyl)-
3,3'-bis(methylamino)-n-methyl-dipropylamine
einecs 204-645-0
methylbis(3-methylaminopropyl)amine
3,3'-methylimino-bis-(n-methylpropylamine)
nsc 166322
n1,n3-dimethyl-n1-(3-(methylamino)propyl)propane-1,3-diamine ,
AKOS015918218
n,n',n''-trimethyldiitrimethylenetriamine
PQYGBJHVVYREGU-UHFFFAOYSA-N
DTXSID8059558
SCHEMBL1231390
J-004975
n,n-bis[3-(methylamino)propyl]methylamine, 98%
GEO-04122
n1,n3-dimethyl-n1-[3-(methylamino)propyl]-1,3-propanediamine
RU2C4AX4WA
n,n-bis[3-(methylamino)-propyl]methylamine
1,3-propanediamine, n1,n3-dimethyl-n1-[3-(methylamino)propyl]-
FT-0706750
mfcd00014857
3,3'-methylimino-bis-(n-methylpropyl-amine)
D97800
n-methyl-3,3'-bis(methylamino)dipropylamine
STARBLD0000245
CS-0456849
n1,n3-dimethyl-n1-[3-(methylamino)propyl]propane-1,3-diamine
SY358373
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bipiperidyl mustard
bipiperidyl mustard: RN given refers to parent cpd; structure		1.9610
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.3620copper group element atom;
elemental gold
piperidines
Piperidines: A family of hexahydropyridines.		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		01.9610
Acid beta-Glucosidase Deficiency
[description not available]		01.9610
Astrocytoma, Grade IV
[description not available]		01.9610
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9610
Gaucher Disease
An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.		01.9610
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		01.9610
Allergic Encephalomyelitis
[description not available]		02.3620
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.3620
Brain Disorders
[description not available]		02.3620
Brain Swelling
[description not available]		01.9610
Froehlich's Syndrome
[description not available]		01.9610
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		02.3620
Brain Edema
Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)		01.9610
Alloxan Diabetes
[description not available]		01.9710